Organofluorides

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Funding for nanomaterials to decontaminate water

Retrieved on: 
Monday, August 2, 2021

The multidisciplinary team wishes to take advantage of the unique properties of nanomaterials to develop new advanced electro-catalytic processes (ECA).

Key Points: 
  • The multidisciplinary team wishes to take advantage of the unique properties of nanomaterials to develop new advanced electro-catalytic processes (ECA).
  • The project aims to create innovative solutions to decontaminate waters containing harmful chemical compounds, such as perfluoroalkyl and polyfluoroalkyl substances (PFAS).
  • "These ECA processes have great potential to decontaminate waters by removing persistent organic pollutants (POPs), such as PFAS.
  • INRS' work in water decontamination is in line with our strategic vision," said Martin Bureau, SANEXEN's Vice President of Innovation.

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

Retrieved on: 
Wednesday, July 28, 2021

Complete data from the Phase 2 clinical study of VX-121/tezacaftor/VX-561 and the VX-561 Phase 2 monotherapy study will be presented at a later date.

Key Points: 
  • Complete data from the Phase 2 clinical study of VX-121/tezacaftor/VX-561 and the VX-561 Phase 2 monotherapy study will be presented at a later date.
  • The primary endpoint in both studies is the absolute change from baseline in ppFEV1, which will be analyzed for non-inferiority to TRIKAFTA.
  • Both studies will also assess absolute change from baseline in ppFEV1 and sweat chloride for superiority to TRIKAFTA.
  • The VX-121/tezacaftor/VX-561 program was granted Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins

Retrieved on: 
Wednesday, July 28, 2021

NAP is developing obicetrapib as an adjunct to maximally tolerated lipid-lowering therapy as a monotherapy and a fixed-dose combination with ezetimibe.

Key Points: 
  • NAP is developing obicetrapib as an adjunct to maximally tolerated lipid-lowering therapy as a monotherapy and a fixed-dose combination with ezetimibe.
  • Top-line results of the ROSE study show unprecedented effects of CETP inhibition on LDL-c reduction and HDL-c increase attributed to orally administered obicetrapib.
  • ROSE (NCT04753606) was designed as a placebo-controlled, double-blind, randomized, Phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
  • A total of 120 patients were randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period.

Global Immersion Cooling Market (2021 to 2026) - Adoption in Low-Density Data Centers Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021

Single-phase type segment is projected to lead the immersion cooling market during the forecast period.

Key Points: 
  • Single-phase type segment is projected to lead the immersion cooling market during the forecast period.
  • Based on type, the single-phase immersion cooling is estimated to grow at the highest CAGR during the forecasted period.
  • In single-phase immersion cooling, the coolant never changes state, i.e., it never boils or freezes and always remains in a liquid form.
  • Due to this, there are no chances of the cooling fluid getting evaporated as it does in two-phase immersion cooling technique.

Global Heat Resistant Polymers Market Report 2021: Market to Surpass $20 Billion by 2027 - Fluoropolymers Segment to Account for $9.1 Billion of the Total Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Heat Resistant Polymers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Heat Resistant Polymers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Fluoropolymers, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$9.1 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $3.9 Billion, While China is Forecast to Grow at 8.5% CAGR
    The Heat Resistant Polymers market in the U.S. is estimated at US$3.9 Billion in the year 2020.
  • In the global Polyphenylene Sulfide segment, USA, Canada, Japan, China and Europe will drive the 6.3% CAGR estimated for this segment.

Global Fluoropolymer Films Market Trajectory & Analytics Report 2021: Market to Reach $3 Billion by 2027 - Polytetrafluoroethylene (PTFE) Segment to Account for $1.5 Billion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Fluoropolymer Films - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fluoropolymer Films - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Fluoropolymer Films estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$3 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.
  • Polytetrafluoroethylene (PTFE), one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$1.5 Billion by the end of the analysis period.
  • In the global Ethylene Tetrafluoroethylene (ETFE) segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment.

Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds

Retrieved on: 
Tuesday, July 20, 2021

Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry.
  • PFAS have been manufactured and used in a variety of industries worldwide since the 1940s.
  • Environmental contamination of PFAS compounds continues to be a highly visible environmental issue.
  • More than 100 PFAS compounds are included in this method covering all important regulations, so customers can stay relevant as regulations are updated, and can also future-proof their PFAS analysis with several emerging PFAS, Anumol added.

Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

Retrieved on: 
Wednesday, July 7, 2021

Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.

Key Points: 
  • Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021.
  • Mr. Dyer will give a corporate update, including an overview of recent advances in Addexs clinical trial program.
  • To learn more about the event or to schedule a one-on-one meeting with Addex management, please visit https://www.accesstogiving.com/ or email [email protected] .
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck

Retrieved on: 
Thursday, July 1, 2021

Lundbeck received options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised.

Key Points: 
  • Lundbeck received options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised.
  • "We are excited to collaborate with Denovo Biopharma and build upon the efforts of our employees, investigators, and patients who participated in our clinical trials to potentially develop a personalized medicine for Alzheimer's Disease," said Keld Flintholm Jrgensen, CBO at Lundbeck.
  • Denovo Biopharma is a clinical-stage biopharmaceutical company that applies novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations.
  • Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial.